Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Keeping Track: Teva's Austedo Clears US FDA, Merck Sitagliptin CV Outcomes Labeling Draws Complete Response

Executive Summary

The latest drug development news and highlights from our FDA Performance Tracker.


Related Content

Merck Blocked In Adding CV Claim For Januvia, May Fall Behind Victoza
Teva’s Austedo Positioned To Compete With A Generic Rival
AML Pipeline Update: Pharmas Pursue Big Breakthroughs In Niche Spaces
Jardiance's Cardiovascular Benefit Claim Bodes Well For Other Products Too
Keeping Track: Chugai Delivers Two Breakthroughs For Roche; FDA Continues To Wrestle With Opioid Regulation
Celator Shines At ASCO, Highlights Upside For Jazz
Keeping Track: FDA Approval Activity Heats Up With Ocaliva, Zinbryta And More
Sitagliptin Shows No Increased Cardiovascular Risk In Merck’s TECOS Trial
Diabetes Drug Labels Should Reflect Heart Failure Risk, FDA Panel Says
Teva Makes A Specialty M&A Play In Deal To Buy Auspex


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts